Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy

Frontiers in Immunology

Immunology

Chenyang Wang¹  Mengshu Li¹  Jiaji Wu¹  Zhiyong Xu¹  Kai Wang¹  Yun Xu¹  Shumin Xu¹  Lingge Yang¹  Peng Xiao² 

[1] Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China;School of Medicine, Zhejiang University, Hangzhou, China;

关键词: immune checkpoints;    tumor associated macrophages;    PD-1;    PD-L1;    SIRP-α;    CD39;    CD73;   

DOI  :  10.3389/fimmu.2023.1199631

 received in 2023-04-03, accepted in 2023-05-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

Unprecedented breakthroughs have been made in cancer immunotherapy in recent years. Particularly immune checkpoint inhibitors have fostered hope for patients with cancer. However, immunotherapy still exhibits certain limitations, such as a low response rate, limited efficacy in certain populations, and adverse events in certain tumors. Therefore, exploring strategies that can improve clinical response rates in patients is crucial. Tumor-associated macrophages (TAMs) are the predominant immune cells that infiltrate the tumor microenvironment and express a variety of immune checkpoints that impact immune functions. Mounting evidence indicates that immune checkpoints in TAMs are closely associated with the prognosis of patients with tumors receiving immunotherapy. This review centers on the regulatory mechanisms governing immune checkpoint expression in macrophages and strategies aimed at improving immune checkpoint therapies. Our review provides insights into potential therapeutic targets to improve the efficacy of immune checkpoint blockade and key clues to developing novel tumor immunotherapies.

【 授权许可】

Unknown   
Copyright © 2023 Xu, Wang, Yang, Wu, Li, Xiao, Xu, Xu and Wang